SCHEMBL4034706

SCHEMBL4034706

FC(F)(F)c1ncc(N2CCC(CC3CCN(C4CCC4)CC3)CC2)cn1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.38
L3MBTL3 Q96JM7 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
LCAT P04180 4/20 0.37
HRH4 Q9H3N8 1/20 0.35
MBTD1 Q05BQ5 1/20 0.35
CHRM4 P08173 3/20 0.34
CHRM2 P08172 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208552 0.85 HRH3 (0.43) HRH3L3MBTL3L3MBTL1LCAT
SCHEMBL4034653 0.80 HRH3 (0.44) HRH3LCATHRH4CHRM4CHRM2
Trifluoroacetic Acid SCHEMBL4034608 0.74 HRH3 (0.48) HRH3L3MBTL3L3MBTL1MBTD1CHRM4
SCHEMBL4033947 0.73 CXCR3 (0.40) HRH3LCAT
SCHEMBL4031344 0.73 HRH3 (0.42) HRH3L3MBTL3L3MBTL1LCAT
SCHEMBL14650270 0.72 MAPT (0.41) L3MBTL1LCATPPARDPPARA
SCHEMBL4032479 0.72 HRH3 (0.53) HRH3L3MBTL3L3MBTL1MBTD1
SCHEMBL4036039 0.72 L3MBTL3 (0.48) HRH3L3MBTL3L3MBTL1MBTD1
SCHEMBL4035015 0.71 HRH3 (0.53) HRH3L3MBTL3L3MBTL1MBTD1
Hydrochloric Acid SCHEMBL4033620 0.70 HRH3 (0.52) HRH3L3MBTL3L3MBTL1MBTD1CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638631-B2 Methylene dipiperidine derivatives GLAXO GROUP LIMITED (GB) 2009-12-29 US claimed
EP-1789410-B1 METHYLENE DIPIPERIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2009-06-17 EP claimed
US-20080108624-A1 Methylene Dipiperidine Derivatives GLAXO GROUP LIMITED (GB) 2008-05-08 US claimed
US-7638631-B2 Methylene dipiperidine derivatives GLAXO GROUP LIMITED (GB) 2009-12-29 US disclosed
US-7638631-B2 Methylene dipiperidine derivatives GLAXO GROUP LIMITED (GB) 2009-12-29 US disclosed
US-7638631-B2 Methylene dipiperidine derivatives GLAXO GROUP LIMITED (GB) 2009-12-29 US disclosed
EP-1789410-B1 METHYLENE DIPIPERIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2009-06-17 EP disclosed
US-20080108624-A1 Methylene Dipiperidine Derivatives GLAXO GROUP LIMITED (GB) 2008-05-08 US disclosed
US-20080108624-A1 Methylene Dipiperidine Derivatives GLAXO GROUP LIMITED (GB) 2008-05-08 US disclosed
US-20080108624-A1 Methylene Dipiperidine Derivatives GLAXO GROUP LIMITED (GB) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108624-A1 Methylene Dipiperidine Derivatives DRD2, DRD4, PNMT HRH3 620/4885L3MBTL3 2451/4885L3MBTL1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.